Five Star Equities Issues New Research Reports on AMRS, ANIK, CERS and EXAM


Follow this company

Companies Mentioned

NASDAQ:AMRS / NASDAQ:ANIK / NASDAQ:CERS / NYSE:EXAM
02/27/2014 [ACCESSWIRE]

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Amyris Inc. (NASDAQ: AMRS) shares surged 26.39 percent to close at $4.55 a share Wednesday. The stock traded between $3.88 and $4.67 on volume of 2.48 million shares traded. The company announced that it expects to “achieve positive cash flow from operations during 2014”. Shares of Amyris are down approximately 14.0 percent year-to-date.

Get more information on Amyris and free access to the in-depth equity report at:  
www.FiveStarEquities.com/AMRS

Anika Therapeutics, Inc. (NASDAQ: ANIK) shares soared 33.16 percent to close at $45.90 a share Wednesday. The stock traded between $43.50 and $52.49 on volume of 6.45 million shares traded. The company announced that MONOVISC has received marketing approval from the FDA for the treatment of osteoarthritis (OA) in the knee. Shares of Anika Therapeutics are up approximately 20.0 percent year-to-date.

Get more information on Anika Therapeutics and free access to the in-depth equity report at:  
www.FiveStarEquities.com/ANIK

Cerus Corporation (NASDAQ: CERS) shares fell 17.23 percent to close at $6.58 a share Wednesday. The stock traded between $6.06 and $7.00 on volume 4.16 million shares traded. The company reported product revenue was $9.2 million for the fourth quarter of 2013, a decrease of 12.0 percent when compared to a year ago. Shares of Cerus are up approximately 2.0 percent year-to-date.

Get more information on Cerus and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CERS

Examworks Group, Inc. (NYSE: EXAM) shares spiked 17.19 percent to close at $35.86 a share Wednesday. The stock traded between $34.63 and $36.85 on volume 2.51 million shares traded. The company reported record revenues of $158.8 million for the fourth quarter of 2013, an increase of 13.8 percent when compared to a year ago. Shares of Examworks Group are up approximately 20.0 percent year-to-date.

Get more information on Examworks Group free access to the in-depth equity report at:  
www.FiveStarEquities.com/EXAM

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:                 
Five Star Equities
info@fivestarequities.com

COMMENTS

Leave a comment...
 * 

Your Name
 *